2019 ANNUAL REPORT

ICCBBA, the international standards organization responsible for the management and development of the ISBT 128 Standard, is a not-for-profit nongovernmental organization in official relations with the World Health Organization (WHO).

ICCBBA Vision, Mission, & Priorities

VISION

Global adoption of ISBT 128 for all medical products of human origin.

MISSION

Enhancing patient safety by promoting and managing the ISBT 128 international information standard for use with medical products of human origin.

PRIORITIES

1. To manage international information standards for transfusion medicine, transplantation, and other applications of medical products of human origin in support of traceability, biovigilance, and patient safety.
2. To liaise with health authorities, regulators, scientific and professional societies, user communities, and vendors on standardization in terminology and information technology.
3. To provide educational programs to promote the value of, and need for, information standards and policies to support traceability and biovigilance.
4. To provide technical consultation regarding the implementation and management of ISBT 128.
5. To lead in the continued development of common data structures for information technology, data processing, exchange and transfer, and labeling for medical products of human origin.

ICCBBA Board Members

ICCBBA is governed by a volunteer Board of Directors comprising leading experts in blood transfusion, cellular therapy, and tissue transplantation from around the world. Board positions are advertised publicly and Board members normally serve six year terms. The current Board of Directors has members from Belgium, Germany, India, The Netherlands, Bhutan, the United States, and the United Kingdom.

Diane Wilson
United States

Timothy L. Pruett
United States

Martin Hildebrandt
Germany

Zbigniew M Szczepiorkowski
United States

John Armitage
United Kingdom

Mahrukh Getshen
Bhutan

Ineke Slaper-Cortenbach
The Netherlands

Joy Mammen
India

Kelly Tilleman
Belgium

The governance role of the Board ensures that ICCBBA is managed in an effective and efficient manner and is appropriately staffed and funded whilst at the same time ensuring a fee structure that is fair and appropriate. As Board Members receive no remuneration, and have no long term association with ICCBBA they can maintain the necessary balance and independence to ensure stakeholders receive good value for money.

In this way the ICCBBA Board of Directors has ensured that ICCBBA has developed in a sustainable and responsible manner since its creation in 1994, and will continue to ensure effective controls and efficiencies as ISBT 128 moves forward as the International Standard for Medical Products of Human Origin.

Operating Income

In US Dollar

Registration Fees	33,387
License Fees - Facilities	1,298,022
License Fees - Vendors	532,835
Forum 25	4,338
TOTAL	**1,868,582**



Staff Costs	1,231,323
Scientific Congresses & Exhibitions	90,558
Technical, Development & Board Meetings	164,086
Office Expenses	42,241
Office Rental	93,929
Donations and Awards	11,547
Professional Services	27,034
Communication Services	39,870
Staff Administrative Travel	7,766
Banking Fees	25,595
Insurance	20,964
Forum 25	185,399
TOTAL EXPENDITURE	**1,940,309**
Net Operating Income	71,727
TOTAL	**1,868,582**



2018 Balance Sheet

In US Dollar

ASSETS

Current Assets	
Cash	354,290
Interest Receivable	1,533
TOTAL CURRENT ASSETS	**355,823**

Equipment	
Office Furniture & Equipment	58,850
Computer Hardware & Software	58,246
Less Accumulated Depreciation	101,423
Total Equipment	**15,673**
Deposits	6,254
Investments	2,974,018

TOTAL ASSETS: 3,351,768

LIABILITES & NET ASSETS

Current Liabilites	
Credit Card Liability	13,335
Other	2,336
Accrued Pension Contributions	27,857
Total Current Liabilities	**43,528**

Net Assets - Unrestricted	
Undesignated	1,506,122
Designated	1,802,118
Total Net Assets	**3,308,240**

TOTAL LIABILITES & NET ASSETS: 3,351,768

A HISTORY OF ICCBBA: 1994 - 1995

The United States Department of Defence and Baxter Healthcare in Deerfield, Illinois provide a three year grant to assist in the establishment of the office where ICCBBA will eventually be created.

In November the first full Board of Directors meeting commences. The Americas Technical Advisory Group (ATAG) is established to advise ICCBBA on needs of users in the Americas.

ISBT Council formally cedes ownership of ISBT 128 to ICCBBA, Inc.

ICCBBA, Inc. receives not-for-profit status from the US Internal Revenue Service.

ICCBBA publishes version 1.0.0 of the document "Bar Code Symbology and Application Specification for Labeling of Whole Blood and Blood Components".

1994

AABB and American Red Cross appoint members to form a Board of Directors for new office. The ISBT Council approves the ISBT 128 Standard and agrees in principle to form ICCBBA by adding members to the CoCBBA Board of directors. CoCBBA was the original Council for Commonality in Blood Banking Automation, Inc. a committee established by the AABB, before evolving into ICCBBA.

An Executive Director is selected and an office opens with space rented from AABB. ICCBBA becomes an official entity.

International Council for Commonality in Blood Banking Automation, Inc.

First official meeting of the North America Technical Advisory Group (NATAG, now ATAG).

1995

In February, ICCBBA's Board of Directors meet, writes bylaws, establishes a budget, and prepares Articles of Incorporation for the subsequent incorporation of ICCBBA in the Commonwealth of Virginia.

The Blood Products Advisory Committee of the FDA votes in March of this year to recommend the use of ISBT 128 in the US according to a timetable presented by ICCBBA, Inc.

Registration and license fees are established and the first vendor registers with ICCBBA.

A HISTORY OF ICCBBA: 1996 - 1998

1996

ICCBBA Board of Directors establishes policies for release of incorporated owned materials.

The Edward Hines Jr., VA Hospital in Illinois, USA, becomes the first blood transfusion facility that registers with ICCBBA in May 1996.

1997

First Product Description Codes were added to the Product Description Code Database in the category of whole blood in July of 1996.

A facility in Norway becomes the 50th vendor that registers with ICCBBA.

Version 1.0.0 of the US Industry Consensus Standard is published.

VERSION 1.1 OF THE PRODUCT DESCRIPTION CODE DATABASE

Talks about about implementing ISBT 128 in Estonia begin in the first meeting of European Technical Advisory Group (ETAG).

ETAG

1998

1,000th facility registers with ICCBBA.

Carolinas Cord Blood Bank, Duke University, becomes the first facility to use ISBT 128 for Cellular Therapy.

ICCBBA TECHNICAL ADVISORY GROUPS
Photo: ATAG Meeting

ICCBBA Technical Advisory Groups (TAGs) are formed to provide stakeholder input to the ongoing development of the ISBT 128 Standard and to provide educational and technical support to facilities implementing ISBT 128.

Estonia becomes the 10th country to be registered with ICCBBA and implemented the use of ISBT 128.

A HISTORY OF ICCBBA: 1999 - 2002

1999

ICCBBA publishes the ISBT 128 US Consensus Standard as a guidance document.

2000

Number of registered facilities reaches 1,500.

4,000th Product Description Code added.

2001

In the United Kingdom, NHS Blood & Transplant is the first tissue facility that registers with ICCBBA.

MEETAG (EMATAG) MEMBERS IN CAIRO, EGYPT

2002

ATTENDING CONGRESSES

On a yearly basis, ICCBBA staff travel to various congresses worldwide to spread awareness of ICCBBA's mission of the global adoption of ISBT 128 for all medical products of human origin.

St. Luke's Episcopal Hospital in Houston, Texas becomes the first facility in the United States to implement ISBT 128 in its blood bank.

A HISTORY OF ICCBBA: 2003 - 2005

2003

The United Kingdom and Switzerland implement ISBT 128 nationally for blood tranfusions.

A facility in Turkey becomes the 100th vendor that registers with ICCBBA.

The 5,000th Product Description Code in the category of blood is added.

Mexico becomes 25th country to have registered facilities licensed to use ISBT 128 with ICCBBA.

2004

Kuwait implements ISBT 128 as a national solution in blood banking.

PROVIDING EDUCATION AND PROMOTION - HONG KONG

ICCBBA BOARD AND STANDARDS COMMITTEE MEETING IN LONG BEACH, CALIFORNIA, USA

2005

Hospitals in Norway start to use secure wristband identification using ISBT 128 data structures.



A HISTORY OF ICCBBA: 2006 - 2008

2006

ICCBBA updates the Product Description Code database by adding 74 product codes for the following countries: US, UK, Canada, Sweden, China, and Singapore.

The 100th Cellular Therapy facility registers with ICCBBA.

ICCBBA publishes the 3rd Edition of "ISBT 128: An Introduction".

ICCBBA publishes Product Code Structure for Tissues, Version 2.0.0.

2007

CTCLAG
CELLULAR THERAPY CODING AND LABELING ADVISORY GROUP

The Cellular Therapy Coding and Labeling Advisory Group (CTCLAG) is formally established to develop terminology and labeling standards for Cell Therapy applications.

The Asia Pacific Technical Advisory Group (APTAG) is formed to advise ICCBBA on the needs of users in the Asia Pacific Region.

The CT advisory group publishes standards for the terminology and labeling of cellular therapy products, further expanding the role of ISBT 128 to a standardized terminology system.

A memorandum was signed with GS1 to cooperate in the area of automatic identification standards to determine how to best handle potential overlap in products coded.

The 150th Cellular Therapy facility registers with ICCBBA.

2008

AABB required its accredited blood banks to implement ISBT 128 by May of 2008.

By mid 2008, Colombia becomes the 50th country to have facilities registered with ICCBBA.

ICCBBA and GS1 co-sponsored a workshop on the labeling of plasma derivatives and worked collaboratively to create standardization in patient identification.

ICCBBA creates One World Award to acknowledge professionals who contribute to the understanding and application of international information standards in transfusion and transplantation medicine.

A HISTORY OF ICCBBA: 2009 - 2011

2009

ICCBBA partners with the International Blood Emergency Planning Action Group (IBEPAG) to carry out a survey that tabulated which blood institutions had implemented or were planning on implementing ISBT 128.

First meeting of the European Tissue Technical Advisory Group (ETTAG) occurs in Krakow, Poland.

The One World Award is Presented to Dr. Charles Munk, its first recipient.

FIRST ONE WORLD AWARD RECIPIENT: DR. CHARLES MUNK

2010



Table of Platelet Additive Solutions

New Name	Citrate#	hosphate	Acetate#	agnesium	Potassium	Gluconate	GlucoseA	Itemate Names	Previous ISBT1 28 Name
PASN	SN	SN	SN	SN	SN	SN	SN		ot named
PAS-A		XX						PAS(1)N	ot named
PAS-B			X					PAS II, PAS-2, SSP, T-Sol	PASII
PAS-C		XX						PAS III, PAS-3, Intersol	PASIII
PAS-D			XX		XX			Composol PS	PAS IIIMgK (note, Composol PS should not have been called PASIIIMgK)
PAS-E		XX		XX				PAS IIIM, SSP+	Not named
PAS-F				XX		X		Plasmalyte A, Isoplate	Not named
PAS-G		XX		XX			XN		ot named

Source: Ringwald, J., Zimmerman, R., and Eckstein, R: The New Generation of Platelet Additive Solution for Storage at 22°C: Development and Current Experience, Transfusion Medicine Reviews, Vol2 0, No 2 (April), 2006 pp 158-164

The journal of the ISBT, Vo
Standard Terminology for Platelet Additive Solutions.

The World Health Assembly passes resolution WHA63.22 which urges Member States to encourage the implementation of globally consistent coding systems for human cells, tissues, and organs.

2011

ICCBBA enters into official relations with the World Health Organization.

DR. CLIVE HOHBERGER: 2011 ONE WORLD AWARD WINNER

First year that ICCBBA becomes ISO 9001 certified.

First conference call for the Regenerative Medicine Technical Advisory Group.

A HISTORY OF ICCBBA: 2012 - 2015

2012

5,000th facility registers with ICCBBA.

First conference call for Milk Banking Technical Advisory Group (MBTAG).

2013

2014

Dr. Edwin A. Steane is presented with the One World Award. Dr. Steane was previously the first Executive Director of ICCBBA as well as one of the original creators of the ISBT 128 Standard.

ICCBBA CELEBRATES 20th ANNIVERSARY IN 2014

WHO-ICCBBA JOINT WORKSHOP IN ANNECY, FRANCE

2015

FDA's Center for Devices and Radiologic Health (CDRH) approves ICCBBA as one of only three issuing agencies for medical device Unique Device Identifiers (UDI) in the US.

The European Commission publishes directive that recognizes ISBT 128 to be compatible with the SEC.



Gameta Szpital Sp. Z O.o. in Poland becomes the first reproductive facility to register with ICCBBA.

ICCBBA releases version 1.0 of the Product Lookup Program.

A HISTORY OF ICCBBA: 2016 - 2018

2016

Version 1.0 of an implementation guide on blood transfusion for resource limited countries is published. The intended audiences of this document are blood transfusion services and hospital blood banks.

ICCBBA creates the Enterprise Grant aimed at supporting organizations working in resource limited countries that develop initiatives that have an impact on information management or traceability.

ICCBBA Enterprise Grant

2017

ICCBBA releases version 1.0 of the Product Lookup Program.



The Eye Bank Association of America (EBAA) requires ISBT 128 barcoding for international shipments for eye banks in North America. ICCBBA releases a guidance document (IG-040) in relation to this.

Enterobiotix, Ltd. In Scotland becomes the first fecal micobiota facility that registers with ICCBBA.

The first Enterprise Grant is awarded to Global Healing, a nonprofit organization based in Berkeley, California, for its proposal to strengthen the quality management system of the blood bank at the Hôpital Universitaire de Mirebalais (HUM) in Haiti.

2018

ICCBBA releases version 1.0 of the Single European Code Builder Tool.



ICCBBA releases version 1.0 of the Cellular Therapy Audit Tool. The tool is intended for auditors to help them assess compliance to ISBT 128 requirements for cellular therapy products as well as used by facilities wanting to perform a self-assessment or a gap analysis as part of their ISBT 128 implementation efforts.

AABB, FACT, JACIE, and NMDP require that ISBT 128 terminology be used when labeling cellular therapy products. AABB Standards for Cellular Therapy requires that all facilities shall implement ISBT 128 labeling by 01 July 2018.

A HISTORY OF ICCBBA: 2019

As of September 2019, there exists 15,707 Product Description Codes across all product categories including blood, cellular therapy, ocular tissues, reproductive tissues, regenerative tissues, organs, milk, fecal microbiota, topical, and other products.

As of July 31st 2019, ICCBBA has 5,401 active facilities registered and growing. There are 4,590 Blood, 911 Cell Therapy, 143 Tissue, 119 Ocular, 55 Reproductive, 10 Milk, 5 Medical Device, and 2 Fecal facilities.

FORUM 25

2019

ICCBBA host Forum 25 in Lisbon, Portugal to celebrate 25th Anniversary

PO Box 11309
San Bernardino, CA 92423-1309
United States of America

Fax: 1 909 793 6214
Phone: 1 909 793 6516
Email: info@iccbba.org